Microdosing GLP-1s: A Maintenance Strategy After Goal Weight
Reaching your goal weight is the easier half. Holding onto it without taking the full GLP-1 dose forever is the harder half. That's where microdosing comes in, and where most patient questions in our follow-up visits land.
What microdosing actually means
Microdosing GLP-1 medications means continuing therapy at a sub-therapeutic dose after the active loss phase, typically a fraction of the dose that drove the weight loss. The goal isn't continued loss; it's maintenance. The medication keeps the appetite-regulation and metabolic benefits you've earned without driving you below your target.
Concrete examples from our clinic:
- Semaglutide: 0.25 mg or 0.5 mg weekly instead of the 2.4 mg full Wegovy dose.
- Tirzepatide: 2.5 mg or 5 mg weekly instead of the 15 mg full Mounjaro/Zepbound dose.
- Frequency reduction: some patients move to every-other-week dosing instead of weekly, with the same per-dose amount.
Why microdosing exists at all
The STEP-1 trial extension and similar long-term data show that when patients stop GLP-1 therapy completely, they regain roughly two-thirds of their lost weight within 12 months. The biology argues against a hard discontinuation, the same hormonal counter-regulation that drives the plateau in the loss phase drives weight regain when the medication leaves.
Ready to start?
$199 Skeptics' Trial, see if it works for you
One-time $199 trial with physician evaluation and, only if a prescription is approved and the dispensing pharmacy can fulfill it for the patient's location, one month of compounded semaglutide; the pharmacy confirms packaging and shipping details before fulfillment. No long-term commitment. Standard care starts with a $119 physician review; medication is separate, and compounded semaglutide programs start at $166/month.
Start the 30-day trialThree options exist for the post-goal phase:
- Continue full dose indefinitely. Maintains weight reliably; expensive; some patients dislike persistent low-grade side effects; cost-prohibitive for many uninsured patients.
- Hard discontinuation. Cheapest in the short term; high regain risk; many patients describe the first 4-6 weeks off the medication as a return of food noise that erases their psychological progress.
- Microdose maintenance. The middle path. Most affordable; minimal-to-no side effects; preserves the appetite-regulation benefits.
How we approach microdosing in our clinic
Microdosing isn't a starter strategy. The standard pathway in our practice:
- Months 1-9: full-dose protocol drives the weight loss.
- Month 9-12 conversation: if the patient is at or near goal and the response curve has flattened, we discuss a microdose taper.
- Taper: step down over 4-8 weeks. Watch the scale, watch food noise, watch energy. Stop tapering at the dose that holds weight steady without side effects.
- Maintenance: follow-up every 3-6 months. Bloodwork and dose check-ins.
The clinical realities (the parts most internet articles skip)
- It's not a hack. Microdosing isn't a trick to get the same effect at a lower price. It's a recognition that maintenance physiology is different from active-loss physiology.
- It still requires a prescription. Microdose semaglutide or tirzepatide is still a prescription medication. We don't dispense outside of a documented physician-supervised protocol.
- It still requires monitoring. The boxed warnings for thyroid C-cell tumors and the contraindications (MTC, MEN-2, severe gastroparesis, pregnancy) all still apply at microdose. Don't discontinue follow-up because the dose got smaller.
- It's not appropriate for active loss. Patients who try to use microdoses to lose weight from the start typically see flat scales, the dose is too low to drive a meaningful caloric deficit.
- Long-term safety data is still maturing. The clinical literature on multi-year microdose maintenance is developing. We err toward more frequent check-ins, not fewer.
Who's a good candidate
- Patient has reached or is near their goal weight on a full-dose protocol.
- Response curve has flattened, additional weight loss isn't accruing at the full dose.
- Patient wants to preserve appetite regulation but is willing to skip the full-dose price and side-effect burden.
- Patient is committed to follow-up visits (every 3-6 months minimum).
- No new contraindications since starting therapy.
Who's not a good candidate
- Patient still has 30+ lbs to lose. Microdose won't drive it.
- Patient has new contraindications (e.g., new pregnancy plan, new gallbladder disease, new pancreatitis history).
- Patient won't commit to follow-up. The risk of unsupervised long-term GLP-1 use isn't worth the cost saving.
- Patient is losing weight beyond what's healthy at maintenance dose. This is rare but happens, the right move is full discontinuation, not continuing a microdose.
Frequently asked questions
What does microdosing GLP-1 mean?
Microdosing GLP-1 medications means using sub-therapeutic doses, typically a fraction of the standard maintenance dose, to preserve metabolic and appetite-regulation benefits without driving continued weight loss. It's a maintenance strategy, not a starter strategy. Examples: 0.25 mg or 0.5 mg semaglutide weekly instead of 2.4 mg; 2.5 mg tirzepatide weekly instead of 15 mg.
Who should microdose GLP-1?
Patients who have reached their goal weight on a full-dose protocol and want to prevent weight regain without the cost or side-effect burden of maintenance at the full dose. We typically discuss microdosing 1-3 months before patients reach goal, and start the taper deliberately rather than abruptly.
Does microdosing work for weight loss?
Microdosing is generally not effective for active weight loss in patients who are still well above their goal, the dose is too low to drive a meaningful caloric deficit. Patients who try microdosing during the active loss phase typically see plateau or only minimal continued progress. Microdosing is for after the loss phase, as a maintenance tool.
What are the side effects of microdosing?
At microdose levels, GI side effects are usually mild, many patients describe an absence of side effects entirely. The boxed warning for thyroid C-cell tumors still applies. The same contra-indications (history of medullary thyroid carcinoma, MEN-2, severe gastroparesis, pregnancy) still rule out microdose therapy.
How long can someone microdose?
In our practice, indefinite long-term microdosing is acceptable when paired with regular physician follow-up, typically every 3-6 months. The clinical literature on multi-year GLP-1 microdose maintenance is still developing; we err on the side of more rather than fewer check-ins.
This article is informational only and not medical advice. Speak with a licensed physician before starting, changing, or microdosing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.